Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
A Study of NH280105 in Healthy Adult Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 11, 2025
Lead Product(s) : NH102
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase II Study to Evaluate NH102 for Depression
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 24, 2025
Lead Product(s) : NH102
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Partnership
Teva and Jiangsu Nhwa Partner to Promote AUSTEDO® Access in China
Details : The partnership focuses on commercializing Teva’s Austedo (deutetrabenazine), FDA-approved for treating tardive dyskinesia and chorea associated with Huntington’s disease.
Product Name : Austedo
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 26, 2024
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Oliceridine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Trevena
Deal Size : $5.5 million
Deal Type : Licensing Agreement
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
Details : Under the license agreement, Nhwa granted a license to develop, manufacture, and commercialize Olinvyk (oliceridine), an opioid medication that is used for the treatment of moderate to severe acute pain in adults, in China.
Product Name : Olinvyk
Product Type : Other Small Molecule
Upfront Cash : $2.5 million
May 31, 2023
Lead Product(s) : Oliceridine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Trevena
Deal Size : $5.5 million
Deal Type : Licensing Agreement
Lead Product(s) : NH102
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Single Ascending Dose Study of NH102 in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 20, 2021
Lead Product(s) : NH102
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Complix Discovery Development Agreement Jiangsu Develop Alphabody Therapeutics
Details : Under the terms of the agreement, Complix has granted an exclusive license to Nhwa to develop, manufacture and commercialize the CPABs resulting from this collaboration in Greater China.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 28, 2021
Lead Product(s) : CY150112
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 09, 2021
Lead Product(s) : CY150112
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mivacurium Chloride
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Recipient : Tang-Du Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 16, 2015
Lead Product(s) : Mivacurium Chloride
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Recipient : Tang-Du Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mivacurium Chloride
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2014
Lead Product(s) : Mivacurium Chloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fentanyl
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Combined Use of Etomidate and Propofol in Painless Gastroscopy.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 31, 2013
Lead Product(s) : Fentanyl
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable